

Value Architects Innovation SCORE Portfolio Trust (2011 SERIES B)

A 2 YEAR UNIT INVESTMENT TRUST

Investment Objective

The Trust seeks to provide investors with the possibility of above-average total return (a total return that exceeds that of the S&P 500 Index over the life of the Trust). The Portfolio Consultant sought to select securities whose historical, fundamental profitability metrics have generally been superior to industry peers or that possess significant amounts of intangible assets in the form of intellectual property. There is no guarantee that the investment objective of the Trust will be achieved.

Strategy of Portfolio Selection

The Trust seeks to achieve its objective through investment in the publicly traded common stock of companies. The portfolio was selected by Value Architects Asset Management LLC (the "Portfolio Consultant"). The Portfolio Consultant sought to select stocks of companies involved in aspects of health care, technology, and/or alternative energy.

Description of Portfolio

The portfolio of the Trust contains 36 issues of equity securities of domestic and foreign companies. 100% of the issues are represented by the Sponsor's contracts to purchase. Based upon the principal business of each issuer and current market values, the following sectors are represented by the common stocks of the companies in the portfolio: Health Care, 45.02%; Industrials, 3.97%; and Information Technology, 51.01%.

| | |
|--|----------------|
| INCEPTION DATE: | March 8, 2011 |
| TERMINATION DATE: | March 12, 2013 |
| INITIAL OFFER PRICE: | \$10.00 |
| MINIMUM INVESTMENT: | 500 units |
| <i>(200 units for purchases by certain qualified retirement accounts (may vary by selling firm))</i> | |
| NUMBER OF ISSUES: | 36 |

| | |
|---|-----------------|
| DISTRIBUTIONS: ¹ | Monthly, if any |
| ESTIMATED FIRST YEAR NET ANNUAL DISTRIBUTION PER UNIT: ² | \$0.0768 |
| CUSIP (CASH): | 831703 855 |
| CUSIP (REINVESTMENT): | 831703 863 |
| FEE-BASED CUSIP (CASH): | 831703 871 |
| FEE-BASED CUSIP (REINVESTMENT): | 831703 889 |
| TICKER: | SMVIAX |

Sales Charges³ (based on a \$10 public offering price):

STANDARD ACCOUNTS

| | | |
|------------------------------|----------|-------|
| Transactional Sales Charges: | Initial | 1.00% |
| | Deferred | 2.45% |
| Creation & Development Fee: | | 0.50% |
| Maximum Sales Charge: | | 3.95% |

The deferred sales charge is a charge of \$0.245 per unit and will be deducted in three monthly installments commencing on July 20, 2011. Investors will not be assessed the initial and deferred sales charge for eligible fee-based accounts and must purchase units in a Fee CUSIP. Please see the prospectus for sales charge details.

FEE/WRAP ACCOUNTS⁴

| | |
|-----------------------------|-------|
| Creation & Development Fee: | 0.50% |
| Maximum Sales Charge: | 0.50% |

Volume Discounts

| PURCHASE AMOUNT ⁵ | SALES CHARGE |
|-----------------------------------|--------------|
| Less than \$100,000 | 3.95% |
| \$100,000 but less than \$250,000 | 3.45% |
| \$250,000 but less than \$500,000 | 3.20% |
| \$500,000 but less than \$750,000 | 2.95% |
| \$750,000 or greater | 2.45% |

¹Distributions, if any, will be made commencing on April 29, 2011. The estimated net annual distribution is expected to decline over time because a portion of the securities included in the portfolio will be sold to pay for organization costs, creation and development fee and deferred sales charge. Distributions will fluctuate as a result of Unitholder redemptions in addition to securities being sold within the portfolio. Distributions are also subject to the ability of issuers to make dividend payments in the future.

²The estimated net annual distributions for subsequent years are expected to be less than estimated distributions for the first year because a portion of the securities included in the Trust portfolio will be sold during the first year to pay for organization costs, the creation and development fee and the deferred sales charge.

³Percentages are based on a \$10.00 per unit offering price. For unit prices other than \$10.00, percentages of initial sales charge, creation and development fee, and deferred sales charges will vary. Early redemption will still cause payment of the deferred sales charge. The table above shows the initial offering period sales charges only.

⁴The creation and development fee is a charge of \$.050 per unit collected at the end of the initial offering period. If the price you pay exceeds \$10 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than \$10 per unit, the creation and development fee will exceed 0.50%.

⁵The volume discount is also applied on a unit basis utilizing a breakpoint equivalent in the above table of one unit per \$10. Please see the Trust prospectus for full details. These discounts are only offered during the initial offering period.

CONTINUED ON BACK.

Investors should consider the Trust's investment objective, risks, charges and expenses carefully before investing. The prospectus contains this and other information relevant to an investment in the Trust. Please advise your clients to read the prospectus carefully before they invest. If a prospectus did not accompany this literature, please contact Hennion & Walsh at (888) 505-2872 to obtain a free prospectus.

HENNION & WALSH is a member of FINRA/SIPC.

2001 Route 46, Waterview Plaza, Parsippany, NJ 07054 (888) 505-2872 www.smarttrustuit.com

Portfolio Holdings as of March 8, 2011

| COMMON STOCKS (100%) | NAME OF ISSUER | TICKER |
|--|-------------------------------|--------|
| Health Care (45.02%) | Abbott Laboratories | ABT |
| | Amgen Inc. | AMGN |
| | ArthroCare Corporation | ARTC |
| | AstraZeneca plc | AZN |
| | Galapagos NV | GLPYY |
| | Gilead Sciences, Inc. | GILD |
| | Hologic, Inc. | HOLX |
| | Immucor, Inc. | BLUD |
| | Immunomedics, Inc. | IMMU |
| | Life Technologies Corporation | LIFE |
| | Medtronic, Inc. | MDT |
| | Novartis AG | NVS |
| | Seattle Genetics, Inc. | SGEN |
| | Smith & Nephew plc | SNN |
| ViroPharma Incorporated | VPHM | |
| Zimmer Holdings, Inc. | ZMH | |
| Industrials (3.97%) | Siemens AG | SI |
| Information Technology (51.01%) | Applied Materials, Inc. | AMAT |
| CA, Inc. | CA | |
| Cisco Systems, Inc. | CSCO | |
| Comtech Telecommunications Corp. | CMTL | |
| Google Inc. | GOOG | |
| Harris Corporation | HRS | |
| Intel Corporation | INTC | |
| Intevac, Inc. | IVAC | |
| Lam Research Corporation | LRCX | |
| Mantech International Corporation | MANT | |
| NetScout Systems, Inc. | NTCT | |
| Oracle Corporation | ORCL | |
| Polycom, Inc. | PLCM | |
| Power-One, Inc. | PWER | |
| Qualcomm, Inc. | QCOM | |
| SanDisk Corporation | SNDK | |
| Telvent GIT | TLVT | |
| Teradyne, Inc. | TER | |
| Tessera Technologies Inc. | TSRA | |

Risk Considerations

An investor can lose money by investing in this Trust. The Trust is not actively managed and will not sell securities in response to ordinary market fluctuations. An investment in this unit investment trust is subject to market risk, which is the possibility that the market values of securities owned by the Trust will decline and that the value of Trust units that you receive in connection with the Trust's termination or a redemption of your units may therefore be less than what you paid for them. There is no guarantee that the Trust will meet its investment objectives, that the securities comprising the portfolio will pay dividends or that the unit price will not decline.

Price fluctuations of particular securities will change the portfolio's composition throughout the life of the Trust. When cash or a letter of credit is deposited with instructions to purchase securities in order to create additional units, an increase in the price of a particular security between the time of deposit and the time that securities are purchased will cause the units to be comprised of less of that security and more of the remaining securities. In addition, brokerage fees incurred in purchasing the securities will be an expense of the Trust and such fees will dilute the existing unitholders' interests.

An investment in a portfolio containing small-cap companies is subject to additional risks, as the share prices of small-cap companies are often more volatile than those of larger companies due to several factors, including limited trading volumes, products, financial resources, management inexperience and less publicly available information.


The risk that the financial condition of the issuers of the securities in the Trust may become impaired or that the general condition of the markets may worsen (both of which may contribute directly to a decrease in the value of the securities and thus in the value of the units).

An investment in a portfolio containing securities of foreign issuers is subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting foreign issuers. Risks associated with investing in foreign securities may be more pronounced in emerging markets where the securities markets are substantially smaller, less liquid, less regulated and more volatile than the U.S. and developed foreign markets.

There is no assurance that any dividends will be declared or paid in the future on the securities.

The sponsor may offer successive Trusts with similar portfolios thereby allowing the investor to pursue the same strategy over a number of years. Investors should consider their ability to pursue investing in successive Trusts, if available. There may be tax consequences associated with investing in the Trust and rolling over an investment from one Trust to the next.

Portfolio Allocation by Sector as of March 8, 2011



Portfolio by Industry as of March 8, 2011

